Nacuity Pharmaceuticals, Inc.
Leader in innovative treatments for oxidative stress
Leader in innovative treatments for oxidative stress
Nacuity Pharmaceuticals, Inc. is a clinical-stage leader in innovative treatments for oxidative stress. The company aims to combat oxidative tissue damage, associated with various blinding eye diseases and chronic conditions. Backed by Foundation Fighting Blindness and RD Fund, Nacuity is focusing on generating proof-of-concept data in clinical programs such as retinitis pigmentosa, cataract, and cystinosis. With its recent $16.50M Series B investment led by Foundation Fighting Blindness, Maxim Group LLC, and Retinal Degeneration Fund, Nacuity is positioning itself as a pioneer in developing potentially first-of-a-kind therapies with broader applications. Founded in 2016 and headquartered in the United States, Nacuity is poised for significant advancements in the Health Care and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $16.50M | 3 |
|
15 Jun 2022 |
| Series A | Unknown | 1 | Hugo Peris | 01 Nov 2017 |
| Venture Round | $1.97M | - | 07 Dec 2016 |
No recent news or press coverage available for Nacuity Pharmaceuticals, Inc..
We care about your data, and we'd love to use cookies make your experience better.
